Pharmacokinetic Study on the Sustained-release Tablets of Labetalol in Dogs

孙建国,王广基,杨海涛,山莽挺,蔡晓辉
DOI: https://doi.org/10.3321/j.issn:1000-5048.2003.06.012
2003-01-01
Abstract:AIM: To study the pharmacokinetics of sustained-release labetalol tablets in dog. METHOD: Labetalol was measured by HPLC using Shimadzu VP-ODS column (5 μm, 150 mm x 4.6 mm ID.) as stationary phase and acetonitrile-0.01 mol/L NaH2 PO4 (28 : 72) as mobile phase. In this experiment we studied the pharmacokinetics and bioavailability of labetalol in dog after a single and multiple dose of sustained-released tablets (the test formulation) or labetalol conventional tablets (the reference formulation) respectively. RESULT: The HPLC method proved to be linear in the range of 0.10-10.0 μg/ml. The lower limit of quantitation is 0.01 μg/ml(S/N > 3). The pharmacokinetic parameters after single dose are k = 0.1187 ± 0.0755 h-1 and 0.0984 ± 0.0255 h-1, tmax = 1.15 ± 0.49 h and 3.83 ± 1.17 h, cmax = 3.19 ± 0.42 μg/ml and 1.97 ± 0.84 μg/ml for reference and for test formulation respectively. After 5 consecutive day, treated with the two formulations, the concentration of labetalol gets to a steady-state level, with the css of 1.84 ± 0.54 and 1.77 ± 0.56 μg/ml (after dosage adjusted) for reference and test formulation respectively. CONCLUSION: The sustained-release tablets of labetalol shows a delayed tmax and lower cmax. The concentration fluctuation is not larger than that of the conventional formulation. The test tablet of labetalol shows an sustained-release profile compared with that of conventional tablet.
What problem does this paper attempt to address?